Jefferies Financial Group Inc. Acquires Shares of 14,782 Teva Pharmaceutical Industries Ltd. $TEVA

Jefferies Financial Group Inc. acquired a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 14,782 shares of the company’s stock, valued at approximately $461,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Global Retirement Partners LLC grew its holdings in Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after acquiring an additional 292 shares during the period. Banque Cantonale Vaudoise grew its holdings in Teva Pharmaceutical Industries by 6.3% during the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after acquiring an additional 306 shares during the period. Ethic Inc. grew its holdings in Teva Pharmaceutical Industries by 1.8% during the fourth quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after acquiring an additional 325 shares during the period. Allworth Financial LP grew its holdings in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Christine Fox sold 21,258 shares of the company’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the sale, the executive vice president directly owned 63,647 shares in the company, valued at $2,247,375.57. This represents a 25.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Amir Weiss sold 10,679 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the sale, the chief accounting officer owned 20,016 shares in the company, valued at $720,576. This represents a 34.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 934,459 shares of company stock valued at $31,122,931. Insiders own 0.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TEVA shares. UBS Group upped their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Bank of America upped their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 2nd. Truist Financial upped their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, Barclays upped their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Stock Up 2.3%

Shares of NYSE:TEVA opened at $35.32 on Friday. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The stock’s fifty day simple moving average is $32.35 and its 200-day simple moving average is $31.33. The company has a market capitalization of $40.61 billion, a P/E ratio of 26.56, a P/E/G ratio of 3.42 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion for the quarter. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.